Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16526-31. doi: 10.1073/pnas.1407123111. Epub 2014 Nov 4.

Abstract

Unregulated acute inflammation can lead to collateral tissue injury in vital organs, such as the lung during the acute respiratory distress syndrome. In response to tissue injury, circulating platelet-neutrophil aggregates form to augment neutrophil tissue entry. These early cellular events in acute inflammation are pivotal to timely resolution by mechanisms that remain to be elucidated. Here, we identified a previously undescribed biosynthetic route during human platelet-neutrophil interactions for the proresolving mediator maresin 1 (MaR1; 7R,14S-dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid). Docosahexaenoic acid was converted by platelet 12-lipoxygenase to 13S,14S-epoxy-maresin, which was further transformed by neutrophils to MaR1. In a murine model of acute respiratory distress syndrome, lipid mediator metabololipidomics uncovered MaR1 generation in vivo in a temporally regulated manner. Early MaR1 production was dependent on platelet-neutrophil interactions, and intravascular MaR1 was organ-protective, leading to decreased lung neutrophils, edema, tissue hypoxia, and prophlogistic mediators. Together, these findings identify a transcellular route for intravascular maresin 1 biosynthesis via platelet-neutrophil interactions that regulates the extent of lung inflammation.

Keywords: inflammation; lung; maresin; platelet; resolution.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Arachidonate 12-Lipoxygenase / metabolism
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism*
  • Bronchoalveolar Lavage Fluid / cytology
  • Cell Hypoxia
  • Chemotaxis, Leukocyte
  • Disease Models, Animal
  • Docosahexaenoic Acids / biosynthesis*
  • Docosahexaenoic Acids / metabolism
  • Docosahexaenoic Acids / pharmacology
  • Docosahexaenoic Acids / physiology
  • Docosahexaenoic Acids / therapeutic use
  • Heterografts
  • Humans
  • Hydrochloric Acid / toxicity
  • Inflammation / metabolism*
  • Inflammation / pathology
  • Lung / drug effects
  • Lung / metabolism*
  • Lung / pathology
  • Male
  • Metabolomics
  • Mice
  • Mice, Inbred BALB C
  • Molecular Structure
  • Neutrophils / metabolism*
  • Platelet Activating Factor / pharmacology
  • Platelet Transfusion
  • Recombinant Proteins / metabolism
  • Respiratory Distress Syndrome / chemically induced
  • Respiratory Distress Syndrome / drug therapy
  • Respiratory Distress Syndrome / metabolism
  • Respiratory Distress Syndrome / pathology
  • Thrombin / pharmacology

Substances

  • 13,14-dihydroxydocosahexaenoic acid
  • 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
  • Platelet Activating Factor
  • Recombinant Proteins
  • Docosahexaenoic Acids
  • Arachidonate 12-Lipoxygenase
  • Thrombin
  • Hydrochloric Acid